Jan 08, 2008 - EnteroMedics Inc. (NASDAQ:ETRM), a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced interim clinical results for the company's Maestro(TM) RF2 System. The Maestro RF2 System is currently being evaluated in 33 obese patients outside the United States in the VBLOC-RF2 clinical feasibility study of the company's proprietary VBLOC(TM) vagal blocking therapy... EnteroMedics' Press release -
Wednesday, January 9, 2008
EnteroMedics, Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
Jan 08, 2008 - EnteroMedics Inc. (NASDAQ:ETRM), a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced interim clinical results for the company's Maestro(TM) RF2 System. The Maestro RF2 System is currently being evaluated in 33 obese patients outside the United States in the VBLOC-RF2 clinical feasibility study of the company's proprietary VBLOC(TM) vagal blocking therapy... EnteroMedics' Press release -